Table 1.
Gastric Cancer Prognostic Factors
| Clinical | Pathologic | Molecular/Genetic |
|---|---|---|
| Sex | Stage (many systems)
AJCC/pTNM Lauren/Ming MI Borrman |
VEGF/VEGF-C expression |
| Primary Site | DNA-repair error | |
| Antrum or pyloric | K-ras mutation | |
| Body or middle 1/3 | c-met amplification | |
| GE junction | K-sam | |
| Depth | Histological type
Diffuse Intestinal Mixed Not available |
C-erb B-2 amplification |
| Tumor localization | EGFR | |
| Lymph nodes | EGF | |
| Venous invasion | TGF alpha | |
| Neovascularization | VEGF | |
| Size | Differentiation (grade) | p53 LOH |
| Presence of bone marrow micro-metastases | p53 (mutation) | |
| Presence of Helicobacter pylori | APC LOH | |
| R classification | uPA system | |
| L/V classification | E-cadherin | |
| Disseminated epithelial cells |
Abbreviations: AJCC = American Joint Committee on Cancer; APC = adenomatous polyposis coli gene; EGF = epidermal growth factor; EGFR = EGF receptor; GE = gastroesophageal; LOH = loss of heterozygosity; L/V = lymphatic/vascular; MI = Maruyama Index; pTNM = pathologic tumor-node-metastasis stage; R = resection; TGF = transforming growth factor; uPA = urokinase-type plasminogen activator; VEGF = vascular endothelial growth factor.